Chi­na boasts 48% price cut on in­sulin as do­mes­tic drug­mak­ers eclipse Big Phar­ma in bulk or­der

In a first, Chi­na has fea­tured in­sulin in its cen­tral­ized drug pro­cure­ment pro­gram — but the bulk or­der comes at a siz­able cost for multi­na­tion­al phar­ma play­ers.

No­vo Nordisk, Sanofi and Eli Lil­ly were among eight com­pa­nies, do­mes­tic and for­eign, whose in­sulin prod­ucts won ten­ders from the Chi­nese pub­lic hos­pi­tal sys­tem. In ex­change, the drugs’ prices were cut, on av­er­age, by 48%, sav­ing the med­ical in­sti­tu­tions a col­lec­tive $1.4 bil­lion on the first batch of 210 mil­lion dos­es, ac­cord­ing to state me­dia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.